Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...

Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the ...

Entresto is considered a cornerstone of Divi’s innovator-driven custom synthesis portfolio, contributing close to 40 percent ...

A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...

Brokerage firm IIFL has warned that due to this development, Divi's Laboratories' annual Earnings Before Interest, Tax, ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Stock recommendations today include HCLTech, Ola Electric, Kalyan Jewellers, and Sun Pharma as analysts review June quarter ...

The company's quarterly core operating profit--the company's preferred earnings metric, which strips out exceptional and other one-off items--is forecast at $5.75 billion, according to the same ...

Washington: In a significant legal setback for Novartis, a Delaware federal judge has said that Swiss pharmaceutical giant ...

Note that some links may require registration or subscription. The Department of Justice said it sent more than 20 subpoenas ...

A U.S. judge ruled against Novartis, allowing MSN Pharmaceuticals to launch a generic version of Entresto prior to its patent expiry next year. Novartis plans to appeal the decision, which could ...